Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,984.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,108.0,1.0,=,9.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,972.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,237.0,1.0,=,4.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,774.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,87.0,1.0,=,8.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,509.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,58.0,1.0,=,8.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,1038.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,305.0,1.0,=,3.4
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,990.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,145.0,1.0,=,6.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,537.0,1.0,Beta,18,L18F + D80A + D215G + Δ242-244 + R246I + K417N + E484K + N501Y + A701V,1,=,246.0,1.0,=,2.2